Novo Nordisk A/S Common Stock (NY:NVO)

NVO Stock Continues To Decline Pre-Market After Monday’s Crash Amid CagriSema Setback – But Tuesday Brings Some Hope From China ↗

Topics Artificial Intelligence

February 24, 2026

Developed in partnership with United Laboratories International Holdings, Novo Nordisk said that UBT251 delivered up to 19.7% mean weight loss after 24 weeks in a phase 2 trial in China.

Got $5,000? Viking Therapeutics Might Be a Weight‑Loss Drug Moon Shot in the Making. ↗

February 23, 2026

Is this the best way to cash in on the weight-loss gold rush?

Today, Feb. 23, 2026, a pivotal obesity‑drug trial setback forces investors to rethink Novo Nordisk’s strategy.

Stock Market Today, Feb. 23: Novo Nordisk Plunges 16% After Obesity Drug Falls Short ↗

February 23, 2026

Stock Market Today, Feb. 23: Nvidia Earnings Loom as Tariff Concerns Drive Dow 800 Points Lower ↗

Topics Stocks

February 23, 2026

AI jitters, tariff shock, and looming Nvidia results have investors fleeing growth for perceived safety, today, Feb. 23, 2026.

Novo Nordisk Shares Tumble 15.1% After CagriSema Fails to Topple Eli Lilly in Head-to-Head Trial

Topics Artificial Intelligence Government Stocks

February 23, 2026

The undisputed reign of Novo Nordisk in the weight-loss drug sector faced its most severe challenge to date on February 23, 2026, as the company’s US-traded shares (NYSE: NVO) plummeted 15.1% in a...

Check out the stocks that are attracting the most attention and driving market activity. ↗

February 23, 2026

Via Chartmill

Why Viking Therapeutics Stock Is Up More Than 9% Today ↗

February 23, 2026

A potential competitive threat to Viking's phase 3 weight-loss drug VK2735 was just dealt a major blow.

Novo Nordisk A/S Investigated on Behalf of Investors - Contact the DJS Law Group to Discuss Your Rights – NVO

February 23, 2026

From The DJS Law Group

Via Business Wire

Why Eli Lilly Stock Just Popped ↗

February 23, 2026

Eli Lilly has some good news for investors today. Novo Nordisk has some bad news (which is also good news for Lilly).

GLP-1 weight loss drug CagriSema may not be the salvation Novo Nordisk was hoping for.

Why Novo Nordisk Stock Just Crashed ↗

February 23, 2026

High Volatility and Earnings Crossroads: A Deep Dive into Hims & Hers Health (HIMS) in 2026

February 23, 2026

As of February 23, 2026, Hims & Hers Health, Inc. (NYSE: HIMS) finds itself at a critical crossroads that has sent shockwaves through the telehealth and pharmaceutical sectors. Once the darling of the...

Via Finterra

Topics Artificial Intelligence Intellectual Property Lawsuit

NVO Investors Have Opportunity to Join Novo Nordisk A/S Fraud Investigation with the Schall Law Firm

February 23, 2026

From The Schall Law Firm

Via Business Wire

Eli Lilly Surges as Novo Nordisk’s "CagriSema" Stumbles in High-Stakes Obesity Head-to-Head

February 23, 2026

Shares of Eli Lilly (NYSE: LLY) climbed 3.5% on February 23, 2026, as the pharmaceutical giant tightened its grip on the multi-billion-dollar obesity market. The rally was fueled by disappointing...

Novo Nordisk Shares Plunge 13% as Next-Gen Weight Loss Drug CagriSema Fails to Topple Eli Lilly in Landmark Trial

February 23, 2026

COPENHAGEN — Shares of the Danish pharmaceutical giant Novo Nordisk (NYSE: NVO) plummeted more than 13% in premarket trading on Monday, February 23, 2026, following the release of highly anticipated...

1 Reason I'm Seriously Considering Novo Nordisk as a Buy‑and‑Never‑Sell Obesity Stock ↗

Topics Earnings

These stocks are moving in today's pre-market session ↗

February 23, 2026

Via Chartmill

February 23, 2026

Novo Nordisk investors get a second bite at the Ozempic apple.

Viking stock has plenty of room to run.

3 Reasons Viking Therapeutics Stock Could 10X if Its Obesity Pipeline Succeeds ↗

February 23, 2026

The company stated that CagriSema demonstrated 23% weight loss in people with obesity, failing to meet its primary endpoint.

Why Is NVO Stock Falling Pre-Market Today? ↗

February 23, 2026

These two healthcare stocks are likely headed higher from their current prices.

Topics Government

2 Unstoppable Dividend Stocks to Buy Right Now for Less Than $200 ↗

February 22, 2026

But it's good news for Eli Lilly, too.

Hims & Hers in Free Fall: Why Analysts See Nearly 150% Upside ↗

February 21, 2026

Via MarketBeat

Novo Nordisk Stock Investors Just Got Great News From Eli Lilly ↗

February 20, 2026

New products are already generating growth.

Is Pfizer Stock the Only Big Pharma Name I'd Buy and Hold Through Any Market Crash? ↗

February 20, 2026

These biotech companies have catalysts ahead.

Topics Intellectual Property

2 Innovative Biotech Stocks That May Climb 58% and 200%, According to Wall Street ↗

February 19, 2026

Eli Lilly is leading the pack in the GLP-1 weight-loss drug market, but this good news won't last forever.

Warning: This Skyrocketing Stock Has a Hidden Risk ↗

February 19, 2026

Novo Nordisk looks attractively priced even though 2026 is likely to be a tough year.

Topics Intellectual Property

Overlooked and Undervalued: Why Novo Nordisk Stock Deserves Attention ↗

February 19, 2026

Hims & Hers is acquiring Eucalyptus and spreading its wings internationally.

Hims & Hers HUGE Acquisition News! ↗

February 19, 2026

Forget Ozempic: This Obesity‑Drug Giant Is Grabbing the Biggest Slice of the GLP‑1 Gold Rush ↗

February 19, 2026

Ozempic's rival is generating blockbuster revenue and gaining market share.

The Trillion-Dollar Pharmaceutical Giant: Eli Lilly Makes History as Weight-Loss Revolution Drives Unprecedented Growth

February 17, 2026

In a historic moment for the global healthcare industry, Eli Lilly and Company (NYSE:LLY) has officially cemented its position as the world’s first pharmaceutical company to surpass a $1 trillion...

NVO Stock Generates Retail Buzz After European Commission Approves 7.2 MG Once-Weekly Dose Of Wegovy Injection ↗

Topics Earnings Economy

February 17, 2026

The approval follows a positive recommendation from the European Medicines Agency and is supported by data from clinical trials involving more than 1,400 participants.